This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
by Zacks Equity Research
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing Biogen (BIIB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
5 ROE Stocks to Profit as Trade War Spurs Volatility
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Top Ranked Momentum Stocks to Buy for August 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 12th.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Top Ranked Momentum Stocks to Buy for August 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 2nd.
Top Ranked Momentum Stocks to Buy for July 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st.
3 Reasons Growth Investors Will Love Biogen (BIIB)
by Zacks Equity Research
Biogen (BIIB) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman
by Zacks Equity Research
Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Top Analyst Reports for Texas Instruments, Blackstone & Northrop Grumman
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Blackstone (BX) and Northrop Grumman (NOC).
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
by Zacks Equity Research
Key highlights of the past week include earnings update, collaborations and other pipeline news.
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
by Zacks Equity Research
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year. Shares rise in pre-market trading
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.